Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Kingsoft Cloud Holdings Limited (KC) 2200 contracts of August 10 puts trade
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41